CTS: Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

Sponsor
University of Washington (Other)
Overall Status
Recruiting
CT.gov ID
NCT02025023
Collaborator
(none)
120
1
4
151
0.8

Study Details

Study Description

Brief Summary

Local injection of 5-fluorouracil into a chalazion (stye) is as effective as local injection of triamcinolone (steroid) and incision and curettage for treatment of chalazia.

Condition or Disease Intervention/Treatment Phase
  • Drug: 5-fluorouracil Injection
  • Drug: Triamcinolone Acetonide
  • Procedure: Incision and Curettage
  • Drug: Triamcinolone Acetonide/5-fluorouracil mixture
Phase 3

Detailed Description

This is a prospective randomized interventional study comparing four current standard-of-care treatments for chalazia: incision and curettage, local injection of triamcinolone, local injection of 5-FU, and local injection of combination triamcinolone/5-FU.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
Study Start Date :
Dec 1, 2013
Anticipated Primary Completion Date :
Jul 1, 2025
Anticipated Study Completion Date :
Jul 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Incision and Curettage

A vertical incision over the area of chalazion will be done. Inflammatory material will be removed and the chalazion capsule will be excised.

Procedure: Incision and Curettage
If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.

Active Comparator: Injection of Triamcinolone Acetonide

0.1 ml of triamcinolone is injected directly in the chalazion.

Drug: Triamcinolone Acetonide
If chalazion present at follow-up, another Triamcinolone injection will be done.
Other Names:
  • triamcinolone
  • Procedure: Incision and Curettage
    If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.

    Active Comparator: Injection of 5-fluorouracil

    0.1 ml of 5-fluorouracil is injected directly in the lesion transconjunctivally.

    Drug: 5-fluorouracil Injection
    If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
    Other Names:
  • 5-FU
  • Procedure: Incision and Curettage
    If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.

    Active Comparator: Injection of triamcinolone/5FU mixture

    0.1 ml of a 4:1 mixture of 4 parts 5-FU and 1 part triamcinolone is injected in the lesion.

    Procedure: Incision and Curettage
    If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.

    Drug: Triamcinolone Acetonide/5-fluorouracil mixture
    If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.

    Outcome Measures

    Primary Outcome Measures

    1. Size of chalazion [4 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Single or multiple chalazia in a single eyelid
    Exclusion Criteria:
    • Chalazia present for less than one month and no previous injection or incision and curettage

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Washington Eye Institute at Harborview Seattle Washington United States 98104

    Sponsors and Collaborators

    • University of Washington

    Investigators

    • Principal Investigator: Matthew M Zhang, MD, University of Washington Eye Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Matthew Zhang, Assistant Professor of Ophthalmology, University of Washington
    ClinicalTrials.gov Identifier:
    NCT02025023
    Other Study ID Numbers:
    • STUDY00003748
    First Posted:
    Dec 31, 2013
    Last Update Posted:
    Feb 6, 2020
    Last Verified:
    Feb 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Matthew Zhang, Assistant Professor of Ophthalmology, University of Washington
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 6, 2020